VBI Vaccines to Present at the Canaccord Genuity 39th Annual Growth Conference
05 août 2019 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Aug. 05, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
Canaccord Genuity Releases Company Update Research Report on CLS Holdings USA, Inc.
25 juin 2019 08h28 HE
|
CLS Holdings USA, Inc.
LAS VEGAS, NV, June 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Canaccord Genuity, the largest independent investment dealer in Canada, has released a company update research report on CLS...
3 Sixty Secure to Present at Canaccord Genuity 2019 Cannabis Conference in New York on May 14
13 mai 2019 11h46 HE
|
3 Sixty Secure
ALMONTE, Ontario, May 13, 2019 (GLOBE NEWSWIRE) -- 3 Sixty Risk Solutions Ltd. (“3 Sixty” or the “Company”) (CSE: SAFE) (OTCQB: SAYFF) (FSE: 62P2) a leader in the risk management and security...
MariMed CEO Fireman to Highlight Progress at Two NYC Investor Conferences
09 mai 2019 08h30 HE
|
MariMed Inc
Tuesday, May 14, 2019 - Canaccord Genuity 3rd Annual Cannabis Conference; Grand Hyatt Hotel, New York, NY Wednesday, May 15th - CannaStocks 2019 Q1 Investor Conference; OTC Markets Group...
Patriot One Presents at Canaccord Genuity 2019 Growth Investor Day
21 janv. 2019 08h00 HE
|
Patriot One Technologies Inc
TORONTO, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Patriot One Technologies Inc. (TSX.V: PAT) (OTCQX: PTOTF) (FRANKFURT: 0PL) (“Patriot One” or the “Company”), makers of the award-winning PATSCAN threat...
Patriot One Provides Corporate Update
20 déc. 2018 08h00 HE
|
Patriot One Technologies Inc
TORONTO, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Patriot One Technologies Inc. (TSX.V: PAT) (OTCQX: PTOTF) (FRANKFURT: 0PL) (“Patriot One” or the “Company”), developer of the award-winning PATSCAN™ covert...
VBI Vaccines Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriter’s Option to Purchase Additional Shares for Aggregate Gross Proceeds of $42.9 Million
18 déc. 2018 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Pricing of $37.5 Million Public Offering
13 déc. 2018 09h05 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Dec. 13, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Proposed Public Offering of Common Shares
12 déc. 2018 16h01 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Dec. 12, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines to Present at the Canaccord Genuity 38th Annual Growth Conference
06 août 2018 16h15 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...